Soluble ZcytoR21, anti-ZcytoR21 antibodies and binding partners and methods of using in inflammation

An isolated ZcytoR21 soluble receptor comprising SEQ ID NO:12.

An isolated ZcytoR21 soluble receptor comprising amino acid residues 136-414 of SEQ ID NO:21.

An isolated ZcytoR21 soluble receptor comprising amino acid residues 24-414 of SEQ ID NO:21.

An isolated ZcytoR21 soluble receptor comprising SEQ ID NO:23.

An isolated ZcytoR21 soluble receptor comprising amino acid residues 159-437 of SEQ ID NO:107.

An isolated ZcytoR21 soluble receptor comprising SEQ ID NO:122.

An isolated ZcytoR21 soluble receptor comprising amino acid residues 136-414 of SEQ ID NO:109.

An isolated ZcytoR21 soluble receptor comprising amino acid residues 24-414 of SEQ ID NO:109.

An isolated ZcytoR21 soluble receptor comprising SEQ ID NO:113.

An isolated ZcytoR21 soluble receptor comprising SEQ ID NO:115.

An isolated ZcytoR21 soluble receptor comprising SEQ ID NO:117.

An isolated ZcytoR21 soluble receptor comprising SEQ ID NO:119.

An isolated ZcytoR21 soluble receptor comprising a first polypeptide comprising SEQ ID NO:115 and a second polypeptide comprising a polypeptide from the group consisting of:

• SEQ ID NOs:
• 117 and 119.

An isolated ZcytoR21 soluble receptor comprising a first polypeptide comprising SEQ ID NO:117 and a second polypeptide comprising a polypeptide from the group consisting of:

• SEQ ID NOs:
• 115 and 119.

The isolated ZcytoR21 soluble receptor of claim 20, wherein the second polypeptide comprises SEQ ID NO:

• 115.

An isolated ZcytoR21 soluble receptor comprising a first polypeptide comprising SEQ ID NO:119 and a second polypeptide comprising a polypeptide from the group consisting of:

• SEQ ID NOs:
• 115 and 117.

An isolated soluble receptor comprising ZcytoR21, wherein ZcytoR21 comprises a polypeptide having a sequence of amino acid residues selected from the group consisting of:

• SEQ ID NOs:9, 12, 23, 122, 113, 115, 117, 119, amino acid residues 136-414 of SEQ ID NO:21, amino acid residues 24-414 of SEQ ID NO:21, amino acid residues 159-437 of SEQ ID NO:107, amino acid residues 136-414 of SEQ ID NO:109, and amino acid residues 24-414 of SEQ ID NO:109, and wherein said soluble receptor reduces the activity of IL-17C (SEQ ID NO:17).

An antibody or antibody fragment that binds to a polypeptide having a sequence of amino acid residues selected from the group consisting of:

• SEQ ID NOs:9, 12, 23, 122, 113, 115, 117, 119, amino acid residues 136-414 of SEQ ID NO:21, amino acid residues 24-414 of SEQ ID NO:21, amino acid residues 159-437 of SEQ ID NO:107, amino acid residues 136-414 of SEQ ID NO:109, and amino acid residues 24-414 of SEQ ID NO:109, and wherein said soluble receptor reduces the activity of IL-17C (SEQ ID NO:17).

A method for treatment of an immune-mediated disease in a patient in need of such treatment comprising the step of administering a pharmaceutical composition comprising a soluble ZcytoR21 receptor.

A method of reducing IL-17C-mediated inflammation comprising administering to a mammal with inflammation an amount of a composition comprising a ZcytoR21 soluble receptor sufficient to reduce inflammation, wherein said ZcytoR21 soluble receptor comprises a a polypeptide having a sequence of amino acid residues selected from the group consisting of:

• SEQ ID NOs:9, 12, 23, 122, 113, 115, 117, 119, amino acid residues 136-414 of SEQ ID NO:21, amino acid residues 24-414 of SEQ ID NO:21, amino acid residues 159-437 of SEQ ID NO:107, amino acid residues 136-414 of SEQ ID NO:109, and amino acid residues 24-414 of SEQ ID NO:109.

A method of treating a mammal afflicted with an inflammatory disease in which IL-17C plays a role, comprising:

• administering an antagonist of ZcytoR21 to the mammal such that he inflammation is reduced, wherein the antagonist comprises (i) an antibody, antibody fragment, or binding polypeptide that specifically binds a polypeptide or polypeptide fragment of ZcytoR21, or (ii) a polypeptide or polypeptide fragment of ZcytoR21;
• and
• wherein the inflammatory activity of IL-17C is reduced.

A method of treating a pathological condition in a subject associated with ZcytoR21 activity comprising administering an effective amount of a ZcytoR21 soluble receptor, wherein said ZcytoR21 soluble receptor comprises a a polypeptide having a sequence of amino acid residues selected from the group consisting of:

• SEQ ID NOs:9, 12, 23, 122, 113, 115, 117, 119, amino acid residues 136-414 of SEQ ID NO:21, amino acid residues 24-414 of SEQ ID NO:21, amino acid residues 159-437 of SEQ ID NO:107, amino acid residues 136-414 of SEQ ID NO:109, and amino acid residues 24-414 of SEQ ID NO:109, thereby treating said pathological condition.

A method of treating a mammal afflicted with an inflammatory disease in which ZcytoR21 plays a role, comprising:

• administering an antagonist of ZcytoR21 to the mammal such that the inflammation is reduced, wherein the antagonist comprises an antibody, antibody fragment, ZcytoR21 soluble receptor or binding polypeptide that specifically binds a polypeptide or polypeptide fragment of ZcytoR21, and
• wherein the inflammatory activity is reduced.